Sponsor: Spectrum Pharmaceuticals, Inc.
A phase 2 trial of Tyrosine Kinase inhibitor Poziotinib for patients with metastatic Non-small Cell Lung cancer containing EGFR or HER2 exon 20 mutation that have undergone at least one prior line of therapy for metastatic disease.
For more information please contact the clinical research department: 631-675-5075